… valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is a possible
treatment option for chronic heart failure … -effectiveness of sacubitril/valsartan use in South Korea …

Background The data on the effects of the angiotensin receptor–neprilysin inhibitor (ARNI)
sacubitril‐valsartan (LCZ696) in chronic heart failure (CHF) patients with end‐stage renal …

… pro-drug sacubitril and valsartan, an angiotensin II … chronic heart failure with reduced
ejection fraction (HFrEF) (1). Clinical practice guidelines have since afforded sacubitril/valsartan a …

… Sacubitril/Valsartan (S/V) in patients affected by heart failure with reduced ejection fraction
(HFrEF). Therefore, we sought to investigate predictors of LA structural and functional reverse …

… /valsartan was introduced into the officially approved therapeutic repertoire for chronic heart
failure (… preliminary data from our experience with sacubitril/valsartan, ie, the first 8 months of …

… valsartan administered for the recommended indication of chronic heart failure (CHF) patients
with New York Heart … with the use of sacubitril/valsartan could be supported by a reverse …

… treated with sacubitril/valsartan has been compared with a … Heart Association (NYHA) class
II/III chronic heart failure (… so far validated sacubitril/valsartan exclusively for the CHF therapy. …

… chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart
failure … Developed with the special contribution of the Heart Failure Association (HFA) of the …

… valsartan has been demonstrated to have cardiovascular benefits in patients with chronic
heart failure … trials assessing the impact of sacubitril/valsartan and ACEI/ARB on health-related …

… 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368 PubMed…